Leverage
Guardant Infinity’s extensive methylation coverage to deliver more precise cancer therapeutics.¹
Guardant Infinity is for Research Use Only. Not for use in diagnostic procedures
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
Epigenomic analysis can dramatically improve sensitivity in MRD detection and cancer monitoring.
Epigenomic profiling can expand patient reach through the identification of novel biomarkers.
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma InfinityAI for BioPharma
Methylation-based molecular response assessment can improve therapy response predictions when compared with genomic-only methods.
